Edoxaban + ASA
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Atrial High Rate Episodes
Conditions
Atrial High Rate Episodes
Trial Timeline
Feb 1, 2016 → Dec 31, 2022
NCT ID
NCT02618577About Edoxaban + ASA
Edoxaban + ASA is a phase 3 stage product being developed by Daiichi Sankyo for Atrial High Rate Episodes. The current trial status is terminated. This product is registered under clinical trial identifier NCT02618577. Target conditions include Atrial High Rate Episodes.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02618577 | Phase 3 | Terminated |
Competing Products
20 competing products in Atrial High Rate Episodes